ISL/ULO

PreclinicalSmall molecule

ISL/ULO is one of 2 small molecule programs targeting Human Immunodeficiency Virus Type 1 (HIV-1) Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Human Immunodeficiency Virus Type 1 (HIV-1) InfectionRecruiting

Human Immunodeficiency Virus Type 1 (HIV-1) InfectionPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Human Immunodeficiency Virus Type 1 (HIV-1) Infection

#DrugCompanyPhaseTrials

BIC/FTC/TAF

Merck & Co.

Preclinical

1 2

ISL/ULO

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalRecruiting

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

NCT07266831

Clinical

Trials by Indication[1]

Human Immunodeficiency Virus Type 1 (HIV-1) Infection1 trial

A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV-1

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07266831·570 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ISL/ULO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ISL/ULO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ISL/ULO. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Merck & Co.

ISL/ULO

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Human Immunodeficiency Virus Type 1 (HIV-1) Infection1 trial

References

Drug Info

Quick Facts

Related News